在严重 Behçet 综合征治疗中,Infliximab 与 Cyclophosphamide 相比
David Saadoun1, Georgina Maalouf1, Matheus Vieira1
1Department of Internal Medicine and Clinical Immunology, Sorbonne Universités, Assistance Publique-Hôpitaux de Paris, Pitié-Salpêtrière University Hospital, Centre national de références Maladies Autoimmunes et systémiques rares, National Reference Centre for Rare Autoinflammatory Diseases and Inflammatory Amyloidosis, INSERM, UMR S959, Immunology-Immunopathology-Immunotherapy, Paris.
与环胺相比,infliximab在严重的贝希特综合征诱导疗法中表现出更高的疗效和安全性. 这项临床试验发现,infliximab在患有血管或神经贝赫塞特综合征的患者中实现了更高的完全响应率,并减少了不良事件.
科学领域:
- 免疫学 免疫学 免疫学
- 类风湿病学 类风湿病学
- 临床试验 临床试验
背景情况:
- 严重的贝塞特综合征需要有效的诱导疗法.
- 环胺和因弗利克西马布是当前的治疗选择.
- 缺乏比较的安全性和有效性数据.
研究的目的:
- 为了比较Infliximab与Cyclophosphamide在严重的贝希特综合征中的疗效和安全性.
- 为了评估22周的完整反应率和不良事件.
主要方法:
- 第二阶段,贝叶斯,多中心随机对照试验.
- 52名患有严重的贝塞特综合征 (血管或神经参与) 的患者被随机分组.
- 治疗组接受了静脉注射的infliximab或cyclophosphamide以及标准化的葡萄糖皮质体治疗方案.
主要成果:
- 因弗利西马布实现了81%的完全响应率,而环胺为56% (差异为29.8%).
- 与循环胺 (64%) 相比,因弗利克西马布 (29.6%) 的不良事件显著减少.
- 严重的不良事件在两组之间是可比的 (15%对12%).
结论:
- 对于严重的贝赫特综合征,因弗利西马布是一种比环胺更安全,更有效的诱导疗法.
- 在22周后,infliximab提供了更高的完整响应率.
- 减少不良事件凸显了因弗力西马布的改善安全性.
更多相关视频
06:35An Immunohistopathologic Study to Profile the Folate Receptor Beta Macrophage and Vascular Immune Microenvironment in Giant Cell Arteritis
Published on: February 8, 2019
07:25In Vitro Methods for Comparing Target Binding and CDC Induction Between Therapeutic Antibodies: Applications in Biosimilarity Analysis
Published on: May 4, 2017
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Drugs for Treatment of Ulcerative Colitis in IBD
Inflammatory Bowel Disease IV: Pharmacological Management
Pharmacologic...
Inflammatory Bowel Disease II: Crohn's Disease
Inflammatory bowel disease, commonly known as IBD, refers to a collection of disorders that lead to persistent inflammation of the gastrointestinal tract. The two types of IBD are ulcerative colitis, which impacts the colon, and Crohn's disease, which can involve any part of the gastrointestinal segment.
Crohn's disease
Crohn's disease is a chronic, systemic inflammatory bowel disease (IBD) that predominantly affects the gastrointestinal tract. It is marked by...
